Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 4/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069154 | 0.86 | RET (0.41) | RETMAPK1NAMPTCTSSGABRA5 | |
| SCHEMBL20158595 | 0.85 | RET (0.41) | RETMAPK1NAMPTMGLLCYP3A4 | |
| SCHEMBL20206025 | 0.85 | HRH3 (0.39) | RETMAPK1CTSSHRH3CYP3A4 | |
| SCHEMBL22857092 | 0.84 | RET (0.40) | RETMAPK1NAMPTMGLLGABRA5 | |
| SCHEMBL20158498 | 0.83 | SMN1; SMN2 (0.43) | RETHRH3CYP3A4SMN1; SMN2 | |
| SCHEMBL20147939 | 0.81 | TSHR (0.49) | SMN1; SMN2 | |
| SCHEMBL20205998 | 0.71 | SMN1; SMN2 (0.40) | RETCYP3A4SMN1; SMN2 | |
| SCHEMBL25504417 | 0.70 | CYP2C19 (0.38) | RETHRH3SMN1; SMN2 | |
| SCHEMBL20069680 | 0.70 | RET (0.38) | RETMAPK1NAMPTCTSSHRH3 | |
| SCHEMBL15492739 | 0.70 | NAMPT (0.43) | MAPK1NAMPTSMN1; SMN2GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383966-A9 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885MAPK1 65/4885NAMPT 3045/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885MAPK1 65/4885NAMPT 3045/4885 |
| US-20200030311-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885MAPK1 65/4885NAMPT 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.